July 11, 2021
The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.
July 04, 2021
The duo from Cleveland Clinic discussed their presentation from AHS 2021 regarding the effects of COVID-19 on access to telemedicine visits among minorities.
June 29, 2021
The director of the Montefiore Headache Center discussed the momentum within the migraine research community as well as some of the more notable presentations from AHS 2021.
June 27, 2021
Deena Kuruvilla, MD, the medical director of the Westport Headache Institute spoke to the potential of e-TNS in the treatment of migraine overall and which gaps in care that it might fill.
June 26, 2021
The vice president of Medical Affairs in Migraine at Impel discussed the clinical takeaways from the STOP 301 trial of intranasal DHE and the advantages that the novel formulation might offer patients with migraine.
June 17, 2021
The director of the Headache Center of Southern California discussed research opportunities for layered treatment approaches in migraine.
June 12, 2021
Neurology News Network for the week ending June 12, 2021.
June 10, 2021
The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed further research to be conducted with the nasal delivery of DHE.
June 10, 2021
The findings support previous data that showed no differences between telemedicine and traditional consultations in HIT-6 assessment scores over a long-term period.
June 10, 2021
The director for the Montefiore Headache Center discussed the COURAGE study and how to effectively use a layered treatment approach with ubrogepant and CGRP monoclonal antibodies.
The Mobile Stroke Unit Paradigm Shift for EMS: Thomas Topley
American Stroke Association Publishes Updated Guidance for Intracerebral Hemorrhage
FDA Accepts New Drug Application for Intranasal Zavegepant to Treat Acute Migraine
Tackling Neurodegeneration in Multiple Sclerosis: Emily Harrington, MD, PhD